Recent advances in the first-line management of advanced RCC (VIRTUAL)
Sponsored by EISAI EUROPE LTD
01 July 2022, 16:15 - 17:15 CEST
Looking towards the future: considerations for treatment strategies across the spectrum of advanced prostate cancer (HYBRID)
Sponsored by JANSSEN EMEA
01 July 2022, 16:15 - 17:45 CEST
Advances in the management of acute and recurrent UTIs caused by resistant pathogens – what’s next? (HYBRID)
Sponsored by GLAXOSMITHKLINE
01 July 2022, 16:15 - 17:45 CEST
Coloplast TFL Drive: a new way to drive settings (ONSITE)
Sponsored by COLOPLAST
01 July 2022, 16:45 - 17:45 CEST
Evolving Concepts in Metastatic Prostate Cancer (VIRTUAL)
Sponsored by PFIZER ONCOLOGY
01 July 2022, 19:30 - 20:30 CEST
Navigating the real-world use of PARP inhibitors in BRCAm mCRPC: a practical discussion (HYBRID)
Sponsored by ASTRAZENECA
02 July 2022, 18:30 - 20:00 CEST
Immuno-Oncology for Muscle-Invasive Urothelial Carcinoma: Exploring Opportunities for Perioperative Use (HYBRID)
Sponsored by BRISTOL-MYERS SQUIBB
02 July 2022, 18:30 - 20:00 CEST
Practical considerations for early-stage bladder cancer: case-based discussions for managing patients with NMIBC and MIBC (HYBRID)
Sponsored by JANSSEN EMEA
02 July 2022, 18:30 - 20:00 CEST
Evidence-based approaches for optimising metastatic hormone-sensitive prostate cancer (mHSPC) patient care: treatment intensification to improve survival (HYBRID)
Sponsored by ASTELLAS PHARMA EUROPE LTD.
03 July 2022, 17:45 - 19:15 CEST
Improvements in prostate cancer management: Focus on imaging and treatment (HYBRID)
Sponsored by TELIX PHARMACEUTICALS
03 July 2022, 17:45 - 19:15 CEST
Advancing patient care in the evolving prostate cancer treatment landscape (HYBRID)
Sponsored by BAYER AG
03 July 2022, 17:45 - 19:15 CEST
Expert Guidance in Non-Muscle Invasive Bladder Cancer: Applying the Latest Recommendations to Clinical Practice (ONSITE)
Sponsored by MEDAC GMBH
03 July 2022, 17:45 - 19:15 CEST